RINX
USPTO CORRECTION PROCESSED BY IB
14/05/2024
Voltar para busca
Dado oficial do USPTO
NRAVEL
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
47
Atualização mais recente
14/05/2024
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5, 42, 44
Data de depósito
23/08/2021
Data de registro
05/12/2023
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
05/12/2023
Última transação
14/03/2024
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
27
Localização do titular
DE
Examinador
ZARICK, DIANA G
Unidade examinadora
N80
Localização atual
TMO LAW OFFICE 126
Titulares e representantes
Titulares
Indivumed GmbH
Representantes
R. Glenn Schroeder Schroeder Law PC
Classificação técnica
Classes Nice
Classe 5Classe 42Classe 44
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical and veterinary preparationsin particular medicines for human beings and animalsfor the treatment of cancermetabolic diseasescardiovascular diseasesinflammatory diseasesdiseases of the immune system; human and animal sample materialsfor medical purposestumor tissues and tissue grafts samplesbloodserumplasmaurinestoolsallograft or xenograft tissue preparationstissue cutsblood plasmablood serumascites being bodily fluidscerebrospinal fluidhuman and animal urine and human and animal stool; test kits of human and animal sample materialscomprising diagnostic reagents for medical purposeshuman and animal allograft and xenograft tissuetissue cuts being biological tissue grafts and biological tissue culturesblood plasmablood serumascites being bodily fluidscerebrospinal fluidhuman and animal urine and human and animal stool; diagnostic preparationsin particular made by using molecular biologicalmolecular geneticgenetic engineeringimmunological and biotechnical methods for medical use; therapeutic preparationsin particular made by using molecular biologicalmolecular geneticgenetic engineeringimmunological and biotechnical methodsfor medical use for the treatment of cancer; biological material collectionsbiological tissue cultures for medical purposes; cancer material collectionsbiological tissue being resected and biopsy tumor and adjacent non-tumor tissue from the human body including epithelialconnectivemuscularnervous tissuesbloodserumplasmaurinestools for medical purposes; medical sample collectionsbiological tissue cultures for medical purposes; biological sample collections from the human bodyepithelialconnectivemuscularnervous tissuesbloodserumplasmaurinestools for medical purposes; biopsy material collectionsbiological tissue in the nature of bloodbiological tissue grafts and biological tissue cultures for medical purposes; all the afore-mentioned in particular with regard to the field of oncology
Classe 42
Collection of clinical data for medical research and development of therapeutics and diagnostics; collecting geneticmedicalbiomedicalbiologicchemical and biochemical data and informationin particular information generated through the use of imaging techniquesthe use of liquid biopsy methodsthe use of histopathological analysis and proceduresthe use of genetic analysis and the use of genomicsproteomicstranscriptomicsmetabolomicslipidomics and/or glycomics studies and analysis for medical research; scientific and technological servicesresearchdesign and development of new technology for others in the field of cancermetabolic diseasescardiovascular diseasesinflammatory diseasesdiseases of the immune system; industrial analysis and research services in the field of cancermetabolic diseasescardiovascular diseasesinflammatory diseasesdiseases of the immune system; design and development of computer hardware and softwarein particular computer programs; scientific research for medical purposesmolecular biologicalimmunological and histological laboratory servicesin particular research and development in the field of human medical and veterinary medical diagnostics and therapy; typing of tissue and tissue samplesin particular using molecular biologicalimmunologicalgenetic engineering and histological methods for research purposes; preparation of human and animal biospecimen for research purposes; providing information and data relating to medical and veterinary research on human and animal biospecimenin particular genomicepigenomicproteomicphosphoproteomicRNAtranscriptomiclipidomic and metabolomic data; medical laboratory services for medical research purposesother than for diagnostic or treatment purposestyping of tissue and tissue samplesin particular using molecular biologicalimmunologicalgenetic engineering and histological methods; database design and development; software as a service (SAAS) serviceshosting software for use by others for use as a database; installationmaintenance and updating of database software; providing scientific research information and results from an online searchable database; programming of computer software for databases; scientific and laboratory analysis using bioinformatics and computational biology in the field of oncology; all the afore-mentioned in particular with regard to the field of oncology
Classe 44
Medical analyses in connection with the treatment of individuals including medical analysis of X-rays and blood samplesmedical testing for diagnostic and treatment purposes; medical clinic services; pharmaceutical advisory services; medical analysis services using bioinformatics and computational biologyfor patient diagnostic and treatment purposes; providing supporting services and advice to hospitals and other medical care centrescollecting and stabilizing of human and animal biospecimensproviding advice related theretothe collection of related clinical data for patient diagnostic and treatment purposes; all the afore-mentioned in particular with regard to the field of oncology
Publicações
Histórico de despachos e eventos da marca no USPTO.
47 publicações encontradas
NURC
NOTICE OF UPDATED REGISTRATION CONFIRMATION EMAILED
23/04/2024
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
08/04/2024
FICS
FINAL DISPOSITION NOTICE SENT TO IB
14/03/2024
FIMP
FINAL DISPOSITION PROCESSED
14/03/2024
CORR
CORRECTION FROM IB ENTERED - NO REVIEW REQUIRED
14/03/2024
COC.
CORRECTION UNDER SECTION 7 - PROCESSED
13/03/2024
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
05/03/2024
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
05/12/2023
R.PR
REGISTERED-PRINCIPAL REGISTER
05/12/2023
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
12/11/2023
RINX
USPTO CORRECTION PROCESSED BY IB
30/10/2023
CRCV
CORRECTION TRANSACTION RECEIVED FROM IB
30/10/2023
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
25/10/2023
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
25/10/2023
GPNX
NOTIFICATION PROCESSED BY IB
24/10/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
19/09/2023
PUBO
PUBLISHED FOR OPPOSITION
19/09/2023
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
30/08/2023
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
30/08/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
30/08/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
11/08/2023
XAEC
EXAMINER'S AMENDMENT ENTERED
11/08/2023
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
11/08/2023
GNEA
EXAMINERS AMENDMENT E-MAILED
11/08/2023
CNEA
EXAMINERS AMENDMENT -WRITTEN
11/08/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
25/07/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
24/07/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
24/07/2023
RFNP
REFUSAL PROCESSED BY IB
28/02/2023
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
26/01/2023
GNRT
NON-FINAL ACTION E-MAILED
26/01/2023
CNRT
NON-FINAL ACTION WRITTEN
26/01/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
21/12/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
21/12/2022
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
21/12/2022
CRSN
CORRECTION SENT TO IB
07/12/2022
CRCR
CORRECTION CREATED FOR IB
07/12/2022
RFNP
REFUSAL PROCESSED BY IB
13/07/2022
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
23/06/2022
RFRR
REFUSAL PROCESSED BY MPU
22/06/2022
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
28/05/2022
CNRT
NON-FINAL ACTION WRITTEN
27/05/2022
MAFR
APPLICATION FILING RECEIPT MAILED
27/05/2022
DOCK
ASSIGNED TO EXAMINER
25/05/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
23/05/2022
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
19/05/2022
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace NRAVEL ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.